肺炎支原体感染与冠心病及阿奇霉素抗感染效果

The Relationship between the Mycoplasma Pneumoniae Infection and Coronary Heart Disease,and the Effects of Anti-infection by Using Azithromyosin

目的探讨肺炎支原体(MP)感染与冠心病(CHD)的关系及阿奇霉素治疗MP感染CHD的效果。方法采用固相酶联免疫吸附(ELISA)方法,对90例冠心病患者和30例健康对照者进行外周血MP抗体IgG检测;90例冠心病患者中血MP抗体IgG阳性的患者,随机分为二组:安慰剂对照组和阿奇霉素治疗组。治疗3个月后复查血清MP抗体lgG。结果冠心病组90例,外周血清MP抗体IgG阳性21例(23.3%),健康对照组30例中MP抗体IgG阳性1例(3.3%),两组比较差异有显著性(P<0.05);阿奇霉素治疗组11例,治疗后MP抗体IgG转阴率为81.8%(9/11),安慰剂对照组10例,治疗后转阴率为50.0%(5/10),两组比较差异有显著性(P<0.01)。结论肺炎支原体感染与冠心病发生发展明显相关;及时、足量的阿奇霉素对MP感染的CHD干预治疗,可提高MP抗体IgG转阴率。

Objective To probe into the relationship between the mycoplasma pneumoniae （MP）infection and coronary heart disease （CHD）as well as the anti-infection effects of Azithromyosin on CHD. Methods The levels of IgG in peripheral serum of 90 CHD patients and 30 healthy controllers were detected by using ELISA. Then the patients were randomly divided into two groups： the placebo group and the Azithromyosin group. Results There were 21 patients with IgG antibody （23.3%） in those 90 CHDones, whereas there was only one patients with IgG antibody （3.3%） in the healthy controllers. There was a significant difference between CHD patients and controllers （P〈0.05） ;There were 11 patients in Azithromyosin group （with a converting ratio of 81.8%） while there were 10 patients in placebo group （with a converting ratio of 50.0%） with a significant difference between the two groups （P〈0.01）. Conclusion The infection of mycoplasma pneumoniae has evidently turned out to be related with the development of coronary heart disease. The intervention therapy in those CHD patients with MP by using adequate Azithromyosin has preferable clinical effects and improve the converting ratio of IgG antibody if they were used in time.